Current state of art for transplantation paradigms in peripheral T-cell lymphomas.

Abstract

Peripheral T-cell lymphomas (PTCLs) are a rare and aggressive lymphoproliferative disorder characterized, with few exception, by poor prognosis. A correct diagnosis is still hampered by the heterogeneity and rarity of disease. Historically, PTCLs were treated like aggressive B-cell lymphoma with anthracycline-based combination chemotherapy with disappointing results. Neither dose intensification nor dose escalation of chemotherapy has been successful in prolonging the survival of PTCL patients. Due to this discouraging scenario, new therapeutic strategies have been tested. A therapeutic program including hematopoietic stem-cell transplantation (SCT) may represent an interesting strategy for high-risk patients. Although no randomized trials are available, autologous SCT may offer a chance of cure in chemosensitive disease. Nonmyeloablative allogeneic SCT has shown a curative potential with limited toxicity, and it is actively being investigated. We will review the role of the current therapeutic approach to PTCL focusing on the most recent advances in SCT.

• Authors: Giulia Perrone, Lucia Farina, Paolo Corradini
• Journal: Expert review of hematology (Expert Rev Hematol) Vol. 6 Issue 4 Pg. 465-74 (Aug 2013) ISSN: 1747-4094 [Electronic] England
• PMID: 23991932 (Publication Type: Journal Article, Review)

Topics

• Hematopoietic Stem Cell Transplantation (methods)
• Humans
• Lymphoma, T-Cell, Peripheral (diagnosis, pathology, surgery)
• Prognosis
• Prospective Studies
• Retrospective Studies
• Treatment Outcome